The link between lipids, statins and cancer: Is there a role for cardio-oncology?

Future Cardiology

Volumn 11, Issue 4, 2015, Pages 389-393

  Jahangir, Eiman ^a   Polin, Nichole M ^a   Lavie, Carl J ^a   Fazio, Sergio ^b  

^a JOHN OCHSNER HEART AND VASCULAR INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cancer; Cardio oncology; Cholesterol; HMG CoA reductase inhibitors; Lipids; Statins

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

BREAST CARCINOMA; CANCER CELL; CARDIO ONCOLOGY; CARDIOLOGY; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CARCINOMA; HUMAN; HYPERLIPIDEMIA; LIPOGENESIS; NEOPLASM; NOTE; ONCOLOGY; PRIORITY JOURNAL; PROSTATE CARCINOMA; COMPLICATION; HYPERLIPIDEMIAS; NEOPLASMS;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; NEOPLASMS;

EID: 84939438739     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/FCA.15.32     Document Type: Note

References (25)

1. Huang C, Freter C. Lipid metabolism, apoptosis and cancer therapy. Int. J. Mol. Sci. 16(1), 924-949 (2015).
2. Jacobs D, Blackburn H, Higgins M et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 86(3), 1046-1060 (1992).
3. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ 308(6925), 373-379 (1994).
4. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 275(1), 55-60 (1996).
5. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278(4), 313-321 (1997).
6. Kitahara CM, Berrington De Gonzalez A et al. Total cholesterol and cancer risk in a large prospective study in Korea. J. Clin. Oncol. 29(12), 1592-1598 (2011).
7. Nelson ER, Chang CY, Mcdonnell DP. Cholesterol and breast cancer pathophysiology. Trends Endocrinol. Metabol. 25(12), 649-655 (2014).
8. Nelson ER, Wardell SE, Jasper JS et al. 27-hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342(6162), 1094-1098 (2013).
9. Allott EH, Howard LE, Cooperberg MR et al. Serum lipid profile and risk of prostate cancer recurrence: results from the search database. Cancer Epidemiol. Biomarkers Prev. 23(11), 2349-2356 (2014).
10. Chen H, Qin S, Wang M, Zhang T, Zhang S. Association between cholesterol intake and pancreatic cancer risk: evidence from a meta-analysis. Sci. Rep. 5, 8243 (2015).
11. Coppola JA, Shrubsole MJ, Cai Q et al. Plasma lipid levels and colorectal adenoma risk. Cancer Causes Control 26(4), 635-643 (2015).
12. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 343(6257), 425-430 (1990).
13. Larosa JC. Pleiotropic effects of statins and their clinical significance. Am. J. Cardiol. 88(3), 291-293 (2001).
14. Ahern TP, Pedersen L, Tarp M et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J. Natl Cancer Inst. 103(19), 1461-1468 (2011).
15. Cholesterol Treatment Trialists C, Baigent C, Blackwell L et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753), 1670-1681 (2010).
16. Garwood ER, Kumar AS, Baehner FL et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res. Treat. 119(1), 137-144 (2010).
17. Hamilton RJ, Banez LL, Aronson WJ et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 116(14), 3389-3398 (2010).
18. Shi M, Zheng H, Nie B, Gong W, Cui X. Statin use and risk of liver cancer: an update meta-analysis. BMJ Open 4(9), e005399 (2014).
19. Walker EJ, Ko AH, Holly EA, Bracci PM. Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study. Cancer 121(8), 1287-1294 (2015).
20. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367(19), 1792-1802 (2012).
21. Pazzaglia S, Saran A, Pariset L et al. Sensitivity of C3H 10T1/2 cells to radiationinduced killing and neoplastic transformation as a function of cell cycle. Int. J. Radiat. Biol. 69(1), 57-65 (1996).
22. Feleszko W, Mlynarczuk I, Balkowiec-Iskra EZ et al. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin. Cancer. Res. 6(5), 2044-2052 (2000).
23. Acar Z, Kale A, Turgut M et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol. 58(9), 988-989 (2011).
24. Cholesterol Treatment Trialists C, Emberson JR, Kearney PM et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE 7(1), e29849 (2012).
25. ClinicalTrials Database: NCT01988571. https://clinicaltrials. gov/ct2/show/ NCT01988571